Sarepta Therapeutics Inc.
SRPT:NASDAQ
Sarepta Therapeutics is a biopharmaceutical company developing RNA-targeted therapeutics that addres serious and life-threatening diseases including Duchenne muscular dystrophy and infectious diseases such as influenza, and the Ebola virus.
Streetwise Company Fact Sheet2026/10/24 2:07:59
(SRPT:NASDAQ)
Analyst coverage
| Bank of America Merrill Lynch — Tazeen Ahmad |
| Oppenheimer & Co. — Kostas Biliouris |
| Needham & Co — Gil Blum |
| Evercore — Gavin Clark-Gartner |
| H.C. Wainwright & Co. — Mitchell Kapoor |
| Barclays — Ellie Merle |
| Morgan Stanley — Michael Ulz |
| Wedbush — Dr. Yun Zhong |
| Wells Fargo & Co. — Dr. Yanan Zhu |
| Freedom Broker — Ilya Zubkov |
Streetwise Reports Articles
| 08/19/2026 - View Article |
| 08/17/2026 - View Article |
| 08/13/2026 - View Article |
| 08/05/2026 - View Article |
| 08/03/2026 - View Article |
Streetwise - Sarepta Therapeutics Inc. Ownership Overview*
Sarepta Therapeutics Inc. (SRPT:NASDAQ)
Restructures
No Restructures for This Company
*Share Structure as of 7/30/2026
© 2026 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
